Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

Inclusion Criteria: 1. Male aged ≥18 and ≤75; 2. Histologically confirmed prostate adenocarcinoma; 3. Evidence of metastasis confirmed by magnetic resonance imaging (MRI)/computed tomography (CT) scan, bone scan, or histology; 4. Clinical stage M1a (distant lymph node positive), M1b (bone metastasis), or M1c (visceral organ metastasis); 5. Prostate cancer has not received local treatment (e.g., prostate radiotherapy, cryotherapy, etc.); 6. The surgeon believes the prostate can be removed; Exclusion Criteria: 1. The surgeon believes the disease is unresectable; 2. Life expectancy less than 2 years; 3. Active spinal cord compression; 4. History of prior local treatment for prostate cancer; 5. Difficulty swallowing, chronic diarrhea, intestinal obstruction, and other factors affecting drug intake and absorption; 6. Refusal to sign the informed consent; 7. Investigator believes the individual is not suitable for inclusion.